Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Drugs - Real World Outcomes|June 27, 2020
Real-World Evidence Studies of Oritavancin Use in Gram-Positive Infections Augment Randomized Controlled Trials to Address Clinical and Economic OutcomesMark Redell
P & T : a Peer-Reviewed Journal for Formulary Management|September 6, 2019
Antibiotic Breakpoints: How Redefining Susceptibility Preserves Efficacy and Improves Patient CareMark Redell, Glenn Tillotson
Frontiers in Pharmacology|May 13, 2022
The Practical Problem With Carbapenem Testing and Reporting Accurate Bacterial SusceptibilitiesMark Redell, Glenn S Tillotson
Open Forum Infectious Diseases|December 2, 2020
Antimicrobial Management of Respiratory Infections in Severe Acute Respiratory Syndrome Coronavirus 2 Patients: Clinical and Antimicrobial Stewardship Programs ConundrumsEllie J C Goldstein, Glenn Tillotson, Mark Redell
Open Forum Infectious Diseases|December 18, 2019
Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient SettingThomas P Lodise, Christina Palazzolo, Kerry Reksc, et al.
Open Forum Infectious Diseases|April 8, 2022
Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of PropertiesRandall K Hoover, Martin Krsak, Kyle C Molina, et al.
Open Forum Infectious Diseases|May 9, 2017
Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical TrialsThomas P Lodise, Mark Redell, Shannon O Armstrong, et al.
Infectious Diseases and Therapy|February 29, 2024
Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical DebridementNicholas W Van Hise, Russell M Petrak, Kairav Shah, et al.
Drugs in R&D|November 27, 2014
Stability and recovery of DIFICID(®) (Fidaxomicin) 200-mg crushed tablet preparations from three delivery vehicles, and administration of an aqueous dispersion via nasogastric tubeAnna Tousseeva, J Derek Jackson, Mark Redell, et al.
Open Forum Infectious Diseases|July 7, 2018
A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO ProgramMark Redell, Greg Moeck, Christopher Lucasti, et al.
Pageof 2